精神病纹状体功能障碍神经影像生物标志物的重复验证
本研究在人类连接组计划早期精神病队列中重复验证功能纹状体异常(FSA)对精神病诊断的区分能力,并评估重测与相位编码方向信度、扫描时长影响及预后价值。结果显示FSA具有良好诊断区分度,但信度中等且与12周抗精神病药症状改善不相关,提示其是可推广的诊断而非预后标志物。
要点
- FSA对精神病诊断区分度良好(AUC=75.4%),非情感性精神病更高(AUC=80.5%)。
- FSA重测信度ICC=0.22–0.48,相位编码方向信度ICC=0.51,总体中等。
- FSA评分与12周抗精神病药症状改善不相关,不支持其预后价值。
核心结论
- FSA是可重复验证的诊断性生物标志物,但不具备预后能力。
研究设计与样本
- 在人类连接组计划早期精神病队列中,比较精神病患者(n=101)与健康对照(n=51)的FSA诊断区分度。
主要发现
- FSA诊断精神病AUC=75.4%(95%CI=67.0-83.3%),非情感性精神病AUC=80.5%(95%CI=72.1-88.0%),情感性精神病AUC=58.7%(95%CI=44.2-72.0%)。
- FSA重测信度ICC范围为0.48(95%CI=0.35-0.59)至0.22(95%CI=0.06-0.36),与内在连接网络参考值相当。
- FSA相位编码方向信度ICC=0.51(95%CI=0.42-0.59),一般低于内在连接网络参考值。
- 扫描时长从2分钟增至10分钟,FSA诊断AUC从71.7%(95%CI=63.1-80.3%)升至75.4%(95%CI=67.0-83.3%),相位编码方向信度从ICC=0.29(95%CI=0.14-0.43)升至0.51(95%CI=0.42-0.59)。
- 在独立队列(n=97)中,FSA基线评分与12周抗精神病药治疗症状改善无相关性。
临床怎么用
- FSA可作为辅助诊断工具用于精神病鉴别,尤其非情感性精神病,但不应作为预后判断依据。
局限性
- FSA重测信度中等,相位编码方向信度一般,扫描时长影响分类准确性与信度。
- FSA与症状改善无相关性,无法预测治疗反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To bring biomarkers closer to clinical application, they should be generalizable, reliable, and maintain performance within the constraints of routine clinical conditions. The functional striatal abnormalities (FSA), is among the most advanced neuroimaging biomarkers in schizophrenia, trained to discriminate diagnosis, with post-hoc analyses indicating prognostic properties. Here, we attempt to replicate its diagnostic capabilities measured by the area under the curve (AUC) in receiver operator characteristic curves discriminating individuals with psychosis (n = 101) from healthy controls (n = 51) in the Human Connectome Project for Early Psychosis. We also measured the test-retest (run 1 vs 2) and phase encoding direction (i.e., AP vs PA) reliability with intraclass correlation coefficients (ICC). Additionally, we measured effects of scan length on classification accuracy (i.e., AUCs) and reliability (i.e., ICCs). Finally, we tested the prognostic capability of the FSA by the correlation between baseline scores and symptom improvement over 12 weeks of antipsychotic treatment in a separate cohort (n = 97). Similar analyses were conducted for the Yeo networks intrinsic connectivity as a reference. The FSA had good/excellent diagnostic discrimination (AUC = 75.4%, 95% CI = 67.0-83.3%; in non-affective psychosis AUC = 80.5%, 95% CI = 72.1-88.0%, and in affective psychosis AUC = 58.7%, 95% CI = 44.2-72.0%). Test-retest reliability ranged between ICC = 0.48 (95% CI = 0.35-0.59) and ICC = 0.22 (95% CI = 0.06-0.36), which was comparable to that of networks intrinsic connectivity. Phase encoding direction reliability for the FSA was ICC = 0.51 (95% CI = 0.42-0.59), generally lower than for networks intrinsic connectivity. By increasing scan length from 2 to 10 min, diagnostic classification of the FSA increased from AUC = 71.7% (95% CI = 63.1-80.3%) to 75.4% (95% CI = 67.0-83.3%) and phase encoding direction reliability from ICC = 0.29 (95% CI = 0.14-0.43) to ICC = 0.51 (95% CI = 0.42-0.59). FSA scores did not correlate with symptom improvement. These results reassure that the FSA is a generalizable diagnostic - but not prognostic - biomarker. Given the replicable results of the FSA as a diagnostic biomarker trained on case-control datasets, next the development of prognostic biomarkers should be on treatment-response data.
引用
- Rubio JM, Lencz T, Cao H, et al. Replication of a neuroimaging biomarker for striatal dysfunction in psychosis. Mol Psychiatry. 2024. PMID: 38177349. doi:10.1038/s41380-023-02381-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。